Starting a thread to discuss the non-invasive test (NIT) landscape for MASH diagnosis and monitoring, because this space is evolving rapidly and I want to make sure I'm up to speed for boards. The three pillars of non-invasive MASH assessment: 1. FibroScan (Vibration-Controlled Transient Elastography) - Measures: Liver stiffness (kPa) for fibrosis, CAP (dB/m) for steatosis - Cutoffs: F0-F1 <7, F2 7-9.5, F3 9.5-12.5, F4 >12.5 kPa - CAP: S0 <238, S1 238-260, S2 260-290, S3 >290 dB/m - Pros: Point-of-care, reproducible, validated, 10-minute test - Cons: Unreliable in obesity (BMI >40 — use XL probe), recent food, active inflammation, ascites. Measures a single dimension of a heterogeneous organ. - AUROC for significant fibrosis: 0.84-0.87 2. ELF (Enhanced Liver Fibrosis) Score - Measures: Serum levels of three direct fibrosis markers (HA, PIIINP, TIMP-1) - Cutoffs: <7.7 no fibrosis, 7.7-9.8 moderate, >9.8 advanced - Pros: Blood test, not operator-dependent, good for monitoring change over time, FDA-cleared - Cons: Expensive (~$300-500), not widely available, affected by age, renal function - AUROC for advanced fibrosis: 0.83-0.90 3. FIB-4 Index - Calculation: (Age x AST) / (Platelet count x sqrt(ALT)) - Cutoffs: <1.3 low risk, 1.3-2.67 indeterminate, >2.67 high risk - Pros: FREE (calculated from routine labs), available everywhere - Cons: Poor in patients <35 or >65, low specificity, lots of indeterminate results - AUROC for advanced fibrosis: 0.76-0.82 The recommended algorithm (AASLD 2023): 1. Calculate FIB-4 in all at-risk patients (metabolic syndrome, T2D, obesity) 2. FIB-4 <1.3 → low risk, reassess in 2-3 years 3. FIB-4 1.3-2.67 → get FibroScan or ELF 4. FIB-4 >2.67 → refer to hepatology, consider biopsy 5. FibroScan >8 kPa or ELF >9.8 → refer to hepatology What are people using in practice? And how are you integrating these into GLP-1 monitoring?

In my community hepatology practice, here's my real-world workflow: Referral triage: - I receive referrals and calculate FIB-4 from the labs they send. If <1.3, I often manage by phone with recommendations and don't bring them in for a visit. - Everyone who comes in gets a FibroScan at the first visit. Baseline assessment for new MASH patients: - FibroScan (stiffness + CAP) - FIB-4 calculation - Comprehensive metabolic panel, CBC with platelets - Lipid panel, HbA1c, fasting insulin - If available and insurance covers: ELF score - If FibroScan >12.5 or diagnostic uncertainty: liver biopsy Monitoring on GLP-1 therapy: - ALT/AST every 3 months for first year - FIB-4 every 6 months (calculated from routine labs) - FibroScan every 6-12 months depending on fibrosis stage - ELF at baseline and 12 months (when insurance covers it) The problem with ELF: It's excellent as a test but the logistics are terrible. Quest and LabCorp both run it, but it requires a special order, costs $300-500, and many insurance plans don't cover it. Medicare does cover it now (as of 2024), which helps for older patients. But for my under-65 patients, it's often out-of-pocket. The problem with FibroScan in the community: I have a FibroScan machine in my office, but most GI practices don't. The nearest FibroScan for many of my patients is a 45-minute drive. This creates a huge access barrier for monitoring. We need FibroScan to be as ubiquitous as ultrasound. Until then, FIB-4 is doing a lot of the heavy lifting in primary care, despite its limitations.

Great discussion. I want to add some emerging NITs that may change the landscape in the next 2-3 years: MAST Score (MRI-AST): - Combines MRI-PDFF, MRI elastography, and AST - AUROC for MASH at-risk: 0.93 (!) - Problem: requires MRI, expensive, limited availability NIS2+ (NASH Diagnostic Panel): - Combines miR-34a, alpha-2 macroglobulin, YKL-40, and HbA1c - Specifically designed to identify "at-risk MASH" (NASH + F>=2) - AUROC: 0.82-0.86 - Commercially available through Labcorp as NASH FibroPanel SomaSignal NASH Score: - Proteomics-based panel measuring >5,000 proteins - Early data shows AUROC >0.90 for MASH diagnosis - Still in development, not commercially available Corrected T1 (cT1) on LiverMultiScan MRI: - Measures inflammation and fibrosis simultaneously - AUROC for NASH: 0.78-0.82 - Available at some centers, reimbursement improving The field is moving toward multimodal assessment — combining serum biomarkers, imaging, and clinical variables into algorithms. A single test will never capture the full complexity of MASH (which involves steatosis, inflammation, ballooning, AND fibrosis). For monitoring GLP-1 response specifically, I think the most practical approach is serial FIB-4 + FibroScan, with ELF as a third data point when available. These three together give you a much more reliable assessment than any single test.

As a patient, can I add some perspective on the non-invasive testing experience? I've now had 4 FibroScans over 18 months. The first two were stressful because I didn't know what to expect. Some practical tips for other patients: 1. Fast for at least 3 hours before. My second FibroScan was after lunch and the stiffness reading was 2 kPa higher than expected. My hepatologist said postprandial blood flow inflates the number. 2. The XL probe matters if you're larger. My first scan used the M probe and failed (unreliable result due to my body habitus — I was BMI 38 at the time). They switched to the XL probe and got a valid reading. If you're above BMI 30-35, ask about the XL probe upfront. 3. Ask for the IQR/median ratio. A good FibroScan should have an IQR/median <30%. If it's higher, the result is unreliable and should be repeated. My third scan had an IQR/median of 38% and my hepatologist ordered a repeat. 4. Don't fixate on a single number. My stiffness readings have been 9.8, 8.2, 7.1, 6.1 kPa. The trend matters more than any single value. 5. The CAP score is less reliable than the stiffness measurement. My hepatologist said CAP has higher variability and she relies on it less for decision-making. I haven't had the ELF test — my insurance denied it twice. I've asked my hepatologist about it and she said it wouldn't change management in my case since we have serial FibroScans.

those are excellent practical points. The IQR/median ratio is actually a quality metric that many operators don't report, so the fact that you know about it is impressive. One thing I want to address for the clinical audience: the biopsy question. Current AASLD guidance says biopsy is needed for: - Diagnostic uncertainty (competing liver diseases) - Clinical trial enrollment - Before starting certain therapies (resmetirom requires biopsy-confirmed NASH) - When NITs are discordant But the trend is clearly moving away from routine biopsy. The reasons: 1. Sampling error: a biopsy captures ~1/50,000th of the liver. Fibrosis is heterogeneous. 2. Complications: ~1/1000 risk of significant bleeding 3. Cost and inconvenience: $3,000-5,000, requires sedation, recovery time 4. Inter-observer variability: pathologists disagree on NAS score ~30% of the time In my training program, we're doing fewer MASH biopsies every year. When I started fellowship, we biopsied nearly every MASH referral. Now we biopsy maybe 20% — only when NITs are discordant or there's diagnostic uncertainty. The drugs are getting so effective that the treatment decision is increasingly based on NIT severity (FibroScan >8 kPa + elevated ALT → treat) rather than histological confirmation. This will only accelerate as more MASH drugs get approved with NIT-based eligibility criteria.